US2021177849A1PendingUtilityA1

Therapeutic Compositions

77
Assignee: ACTELION PHARMACEUTICALS LTDPriority: Aug 29, 2006Filed: Feb 25, 2021Published: Jun 17, 2021
Est. expiryAug 29, 2026(~0.1 yrs left)· nominal 20-yr term from priority
Inventors:Martine Clozel
A61K 31/513A61K 31/506A61K 31/519A61K 45/06A61P 9/12A61P 15/10A61K 31/53A61P 9/00A61P 9/08A61K 31/4985A61P 9/10A61K 31/505A61P 9/04A61P 11/00A61P 43/00
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for the treatment of pulmonary arterial hypertension comprising administering simultaneously, separately, or over a period of time, to a patient in need thereof, an effective amount of a compound of formula (I): 
       
         
           
           
               
               
           
         
       
       in free or pharmaceutically acceptable salt form, and at least one compound having PDE5-inhibitory properties, in free or pharmaceutically acceptable salt form. 
     
     
         2 . The method of  claim 1 , wherein the compound of formula (I) and the compound having PDE5-inhibitory properties are administered simultaneously. 
     
     
         3 . The method of  claim 1 , wherein the compound of formula (I) and the compound having PDE5-inhibitory properties are administered separately. 
     
     
         4 . The method of  claim 1 , wherein the compound of formula (I) and the compound having PDE5-inhibitory properties are administered over a period of time. 
     
     
         5 . The method of  claim 4 , wherein the interval between the administration of the compound of formula (I) and the administration of the compound having PDE5-inhibitory properties does not exceed two days. 
     
     
         6 . The method of  claim 5 , wherein the interval does not exceed one day. 
     
     
         7 . The method of  claim 1 , wherein the compound having PDE5-inhibitory properties is sildenafil, vardenafil, tadalafil, or udenafil. 
     
     
         8 . The method of  claim 1  wherein the compound having PDE5-inhibitory properties is sildenafil. 
     
     
         9 . The method of  claim 1 , wherein the compound having PDE5-inhibitory properties is tadalafil.

Join the waitlist — get patent alerts

Track US2021177849A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.